KS Biomedix: Fitting in the RA crowd

With five rheumatoid arthritis drugs on the market and about 25 others in development, new compounds breaking into the market face stiff competition. KS Biomedix Holdings plc believes its CBF-BS2, a naphthoquinone derivative, has the ability to take market

Read the full 394 word article

How to gain access

Continue reading with a
two-week free trial.